Pharmaceutical Firms Vie for Share of $100 Billion Obesity Drug Market

A wave of pharmaceutical and biotech companies are aggressively developing new weight-loss drugs to challenge the market dominance of Novo Nordisk and Eli Lilly. The intense competition is aimed at securing a share of a rapidly expanding sector that analysts, cited by Reuters, project could reach $100 billion in annual sales within the next decade.

The Race to Challenge the Leaders

While Novo Nordisk's Wegovy and Eli Lilly's Zepbound are the current market leaders, a host of major pharmaceutical firms are advancing their own candidates through clinical trials, often through strategic acquisitions and licensing deals. The focus of this new wave of development is on creating more convenient oral therapies, less frequent injections, and drugs with improved efficacy or side-effect profiles.

Key developments from major challengers include:

• Pfizer: The company is targeting a 2028 approval for its first weight-loss drug, a once-monthly injection known as PF-3944. The drug led to up to 12.3% weight loss at 28 weeks in a study of patients without diabetes.
• Roche: Following its $2.7 billion acquisition of Carmot Therapeutics, Roche is developing CT-388, a weekly injection that produced up to 22.5% weight loss in a mid-stage trial, according to a January report.
• Amgen: The company is conducting six late-stage trials for its experimental drug MariTide across obesity and related conditions, after a mid-stage trial showed it helped patients lose up to 20% of their body weight in a year.
• AstraZeneca: Through licensing deals, the British-Swedish drugmaker is developing multiple candidates, including an experimental pill, elecoglipron, which helped patients achieve a mean weight loss of 11.8% after 36 weeks in a mid-stage trial.
• Merck: The company entered the race for an oral treatment by signing a licensing deal worth up to $2 billion for an experimental pill from Chinese biotech Hansoh Pharma.

Ad

Leaders Innovate Amidst Competition

Market leaders Novo Nordisk and Eli Lilly are not standing still, pushing forward their own next-generation therapies to maintain their lead. Both companies are also competing fiercely in the shift toward oral medications, with pill versions of their blockbuster drugs recently gaining regulatory approvals.

Eli Lilly's experimental drug retatrutide has shown particularly strong results, helping patients lose more than 28% of their weight over a year and a half in a key trial. The company plans to submit the drug for regulatory approval in the first quarter of next year. Similarly, Novo Nordisk is developing several new treatments, including a next-generation injection called amycretin and CagriSema, which it is positioning as a potent successor to Wegovy.